A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
- Conditions
- Alopecia areata (AA)Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2022-502700-78-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 603
Have severe areata alopecia (AA) for at least 1 year, Current AA episode of at least 6 months’ duration with hair loss encompassing =50% of the scalp, Current episode of severe to very severe alopecia areata of less than 8 years. - Participants who have severe AA for = 8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years
Participants must not have primarily diffuse” type of alopecia areata, Participants must not be currently experiencing other forms of alopecia or any other health problem that would make it difficult to see how the study drug is working on alopecia areata, Participants must not have topical applied to scalp within 4 weeks of randomization
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method